Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
September 27th, 2024
Endothelial/vascular aging and atherogenesis are key mechanisms that promote the development of cardiovascular diseases. The present protocol describes methods to evaluate arterial stiffness, endothelial dysfunction, and atherogenesis in patients with related risk factors, which are highly valuable in the cardiovascular research field.
Vascular aging and atherogenesis are key mechanisms promoting cardiovascular diseases, particularly in the presence of risk factors like diabetes, hypertension, and other metabolic dysfunctions. Pulse-wave velocity, flow-mediated dilation and carotid intima-media thickness evaluate arterial stiffness, endothelial dysfunction, and subclinical atherogenesis, providing highly valuable information about patients'cardiovascular profile. Using combined methods to assess vascular health, we found that patient with metabolically unhealthy obesity had lower values of flow-mediated dilation, or FMD, and plasma nitric oxide than patient with metabolically healthy obesity.
This finding provide information leading to prevention, early intervention, and reduction of cardiovascular diseases in population at risk. Determination of vascular elasticity and compliance as well as mediators of vasodilation and atherosclerosis provide a more comprehensive evaluation of vascular health and disease, leading to improved risk stratification and early intervention in the metabolic syndrome population. Our hemodynamic parameters, FMD and CIMT, represent useful diagnostic tools for evaluating cardiovascular risk.
Future challenges for these methods include a combined prognostic interpretation where research is still evolving. To begin, place the patient in a supine position for at least five minutes before beginning the assessment. Place a brachial cuff and secure it around the patient's arm centered on the brachial artery.
Then connect the brachial cuff tube to the SphygmoCor device tube. Press the Start button of the device two times for aortic pressure measurement. Obtain pulse-wave analysis, or PWA, by applanation tonometry.
After scaling the arterial pressure waveform, analyze the systolic part of the waveform, also considering biometric and demographic data. Then obtain an automatic report of the test containing aortic parameters. Proceed to perform carotid femoral pulse wave velocity, or cfPWV, determination through applanation tonometry method.
Place a femoral cuff around the patient's thigh as high as possible, ensuring the tube is centered at the top of the leg. To find the carotid pulse on the patient's neck below the jaw, ask the patient to rotate their head slightly aside. Once the carotid pulse is found at the strongest perceived site, place an indicator mark on the patient's skin.
Obtain three measurements:first, the distance between the carotid pulse and the suprasternal notch;second, the distance between the suprasternal notch and the femoral cuff;and, finally, the distance between the femoral artery by palpating the pulse on the patient's groin and the femoral cuff. Then introduce information on the three distances into SphygmoCor XCEL software. Now connect the femoral cuff tube to the SphygmoCor device tube.
Place the tip of the tonometer on the site where the carotid pulse was previously located, then press the Start button and estimate the cfPWV. To perform the flow-mediated dilation, or FMD, place a high-resolution linear transducer in B mode coupled to the compatible analysis software on the brachial artery. Using a sphygmomanometer, place the cuff around the patient's right forearm.
Scan longitudinally five to 10 centimeters above the elbow. After cuff deflation, perform a continuous record of the longitudinal image of the brachial artery for three minutes and determine the diameter again. To perform the carotid intima-media thickness or CIMT measurement, apply a four-megahertz ultrasonographic probe to identify neck vascular structures such as the carotid artery and jugular vein, as well as the thyroid gland, in a transverse orientation at the base of the neck.
Locate the right carotid artery using a transverse orientation of the transducer, moving in a cephalic direction until the carotid bulb and the bifurcation of the internal and external carotid artery are identified. Then rotate the transducer 90 degrees to achieve a longitudinal view of the carotid bulb. Determine CIMT by measuring the distance between the intima-lumen and media adventitia interfaces along a one-centimeter range distal from the carotid bulb.
The subjects in the metabolically unhealthy obese, or MUO, group exhibited lower values of FMD compared to the metabolically healthy obese, or MHO, group. However, no statistical differences were found in CIMT.
Overview
This study investigates the mechanisms of vascular aging and atherogenesis, which are critical in the development of cardiovascular diseases. The protocol outlines methods for assessing arterial stiffness, endothelial dysfunction, and atherogenesis in patients with risk factors.
Key Study Components
Area of Science
- Cardiovascular Health
- Vascular Biology
- Clinical Research
Background
- Vascular aging and atherogenesis contribute significantly to cardiovascular diseases.
- Risk factors such as diabetes and hypertension exacerbate these conditions.
- Understanding vascular health is crucial for prevention and intervention.
- Evaluating arterial stiffness and endothelial function provides insights into cardiovascular risk.
Purpose of Study
- To evaluate arterial stiffness and endothelial dysfunction in patients.
- To assess the impact of metabolic health on vascular parameters.
- To improve risk stratification and early intervention strategies.
Methods Used
- Pulse-wave velocity measurement for arterial stiffness.
- Flow-mediated dilation (FMD) assessment for endothelial function.
- Carotid intima-media thickness (CIMT) evaluation for atherogenesis.
- Comparative analysis of metabolically healthy vs. unhealthy obesity.
Main Results
- Patients with metabolically unhealthy obesity showed lower FMD and plasma nitric oxide levels.
- Combined assessments provide a comprehensive view of vascular health.
- Identifying vascular elasticity and compliance aids in understanding cardiovascular risk.
- FMD and CIMT are effective diagnostic tools for cardiovascular evaluation.
Conclusions
- Comprehensive vascular assessments can lead to better prevention strategies.
- Early intervention is crucial for populations at risk of cardiovascular diseases.
- Understanding the relationship between metabolic health and vascular function is essential.
Frequently Asked Questions
Executive Industry Relevance
Non-invasive vascular assessments such as pulse-wave velocity, flow-mediated dilation, and carotid intima-media thickness provide critical early-stage insights into cardiovascular risk in populations with metabolic syndrome. These quantitative measures enable biopharma teams to stratify risk, clarify disease mechanisms, and inform translational research decisions for metabolic and cardiovascular portfolios. Integrating these endpoints supports predictive confidence and mechanistic de-risking at key discovery and preclinical inflection points.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of vascular aging and atherogenesis pathways in metabolic disease models.
- Supports biological de-risking by quantifying arterial stiffness and endothelial dysfunction.
- Facilitates functional target validation for vascular and metabolic disease programs.
- Provides mechanistic data to inform predictive confidence and portfolio triage.
Screening & Assay Development
- Establishes validated, quantitative endpoints for vascular health in preclinical models.
- Supports assay standardization and reproducibility for cross-study comparisons.
- Enables scalable screening of interventions targeting vascular function.
- Delivers reliable readouts for compound evaluation in metabolic syndrome contexts.
Translational & Preclinical Research
- Aligns preclinical vascular endpoints with translational biomarker strategies.
- Supports continuity from early discovery through preclinical risk assessment.
- Enables risk-adjusted advancement decisions based on subclinical disease progression.
- Provides predictive de-risking for cardiovascular and metabolic therapeutic candidates.
Pipeline & Workflow Integration
These vascular assessment methods integrate into the discovery-to-preclinical continuum, supporting hypothesis testing, target validation, and translational biomarker alignment for metabolic and cardiovascular programs.
- Discovery Biology: Quantifies arterial stiffness and endothelial function to clarify disease mechanisms and validate targets.
- Screening: Provides standardized, reproducible endpoints for evaluating intervention effects on vascular health.
- Analytics: Delivers quantitative readouts (PWV, FMD, CIMT) for robust statistical comparison across metabolic phenotypes.
- Translational Research: Bridges early mechanistic findings with clinical biomarker strategies for vascular risk.
- Enterprise Reuse: Offers a reusable platform for vascular risk assessment across metabolic and cardiovascular pipelines.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in vascular risk assessment.
- Operational Value: Enables standardized, scalable, and reproducible measurement of vascular endpoints.
- Strategic Value: Supports informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Facilitates risk-adjusted prioritization and advancement of metabolic and cardiovascular assets.
Implementation Considerations
- Requires expertise in vascular imaging and hemodynamic measurement techniques.
- Needs access to validated instrumentation such as SphygmoCor and high-resolution ultrasound systems.
- Demands cross-team standardization of measurement protocols and data analysis.
- Adaptation may be needed for different preclinical or clinical model systems.
- Interpretation of combined prognostic outputs remains an evolving research area.
Biopharma FAQs
Chapters in this video
0:00
Introduction
2:04
Evaluation of Vascular Aging Using Arterial Stiffness for Assessment of Cardiovascular Risk
4:13
Evaluating Endothelial Dysfunction Using Flow‐Mediated Dilation and Subclinical Atherogenesis Using Carotid Intima‐Media Thickness for Cardiovascular Risk Assessment
